Taiwan NHI Pre-screening: Publication of ValueSet for Coverage Indications
ValueSet: NHI-健保事前審查-給付適應症值集
Summary
The National Health Insurance (NHI) in Taiwan has published a ValueSet defining 'Pre-screening - Coverage Indications.' This technical specification, based on FHIR standards, is designed to be integrated into the clinical billing and reimbursement process.
Details
This document provides the definition for the 'NHI Pre-screening - Coverage Indications ValueSet' from Taiwan's National Health Insurance (NHI), adhering to the FHIR (HL7® FHIR® Standard) R4. This ValueSet is crucial for standardizing the coding of specific indications and drug usage for various cancer treatments, determining eligibility for insurance coverage. Specific examples include detailed indications and item codes for different stages of malignant tumors such as breast cancer, gastric cancer, and lung cancer. Technically, this specification is vital for electronic medical record systems and claims processing systems in healthcare facilities. It allows the automated recording and validation of treatment reasons or drug usage, thereby standardizing the billing process. The utilization of this ValueSet significantly enhances data exchange accuracy and efficiency, contributing to the development of Taiwan's advanced medical information interoperability infrastructure.
Original content copyright by respective publishers